Market closedNon-fractional

Cabaletta Bio/CABA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Cabaletta Bio

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Ticker

CABA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Philadelphia, United States

Employees

119

Cabaletta Bio Metrics

BasicAdvanced
$364M
Market cap
-
P/E ratio
-$1.73
EPS
2.47
Beta
-
Dividend rate
$364M
2.47
12.657
12.455
0.345
3.684
-31.16%
-49.06%
1.65
1.65
-5.083
-4.11%
4.42%

What the Analysts think about Cabaletta Bio

Analyst Ratings

Majority rating from 11 analysts.
Buy

Cabaletta Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$25M
20.19%
Profit margin
0.00%
NaN%

Cabaletta Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 7.23%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.37
-$0.37
-$0.46
-$0.51
-
Expected
-$0.44
-$0.40
-$0.39
-$0.48
-$0.55
Surprise
-16.38%
-8.33%
17.23%
7.23%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cabaletta Bio stock?

Cabaletta Bio (CABA) has a market cap of $364M as of July 06, 2024.

What is the P/E ratio for Cabaletta Bio stock?

The price to earnings (P/E) ratio for Cabaletta Bio (CABA) stock is 0 as of July 06, 2024.

Does Cabaletta Bio stock pay dividends?

No, Cabaletta Bio (CABA) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Cabaletta Bio dividend payment date?

Cabaletta Bio (CABA) stock does not pay dividends to its shareholders.

What is the beta indicator for Cabaletta Bio?

Cabaletta Bio (CABA) has a beta rating of 2.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Cabaletta Bio stock

Buy or sell Cabaletta Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing